Join to View Full Profile
1 Childrens PlSaint Louis, MO 63110
Phone+1 314-454-6051
Fax+1 314-454-6225
Dr. Shepherd is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Pediatric Endocrinology, 2005 - 2008- Washington University/B-JH/SLCH ConsortiumResidency, Pediatrics, 2003 - 2005
University of Illinois College of MedicineClass of 2003
Certifications & Licensure
CA State Medical License 2017 - 2027
IL State Medical License 2008 - 2026
MO State Medical License 2008 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Endocrinology
Clinical Trials
- Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor Start of enrollment: 2010 Mar 01
- Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2011 May 06
- Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer Start of enrollment: 2012 Jan 23
- Join now to see all
Publications & Presentations
PubMed
- A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer...Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, Leonard J Appleman, Fei Ding
Breast Cancer Research and Treatment. 2023-04-01 - 6 citationsA phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovari...Julia Manzo, Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin
Cancer Chemotherapy and Pharmacology. 2022-05-01 - 189 citationsInfigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multice...Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla
The Lancet. Gastroenterology & Hepatology. 2021-10-01
Press Mentions
- Fore Biotherapeutics Presents Positive Interim Data from Phase 1/2a Trial Evaluating FORE8394 in Patients with Advanced Tumors with Activating BRAF Alterations at ESMO 2022September 12th, 2022
- Chutes & Ladders—Another Novartis Exec Answers the Biotech Call, This Time for Gene Therapy Startup TevardMay 21st, 2021
- BioSpace Movers & Shakers, May 21May 20th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
